Bioinformatics Software | QIAGEN Digital Insights

OmicSoft Studio: RNA-seq and expression data analysis
2024-08-22 13:00 - 14:30 (America/Halifax) | Virtual - Americas - EST, United States
In this 90-minute training, attendees will learn how to use basic expression analysis (example RNA-seq) functionalities in QIAGEN OmicSoft Studio and how that integrates with OncoLand, DiseaseLand and Single Cell Land. This webinar will focus on expression data analysis using QIAGEN OmicSoft Studio’s powerful analysis and visualization capabilities to explore your ‘omics data:

Accepted data formats (ex. fastq files, cell matrix files with raw or normalized counts, etc.)
Easily generating and flexibly customizing downstream outputs such as differential expression, heatmaps, counts, PCA/PCOA, etc.
Exporting high-resolution graphics as well as raw or filtered tables

To get most out of this training, please consider reviewing the below ahead of time (not a requirement to attend the training though).

Step-by-step local analysis
Step-by-step server analysis

IPA deep dive: miRNA investigation using QIAGEN Ingenuity Pathway Analysis (IPA)
2024-08-27 13:00 - 14:30 (America/Halifax) | Virtual - Americas - EST, United States
In this 90-minute training session, you will learn how to identify target mRNAs for your miRNAs of interest and associate them with pathways, diseases, biological functions, tissues and cell types.
Topics that will be covered include:

How to analyze miRNA-seq datasets alone or both miRNA and corresponding mRNA datasets together
How to use QIAGEN IPA without a dataset, using miRNA IDs
Introduction to databases and curated content specific to miRNA
How to effectively apply various filters and functionalities to identify biomarkers, key targets and biological mechanisms

Learn more about IPA or request for a trial.

Public single-cell expression data made easy with QIAGEN IPA
2024-08-29 13:00 - 14:00 (America/Halifax) | Virtual - Americas - EST, United States
Many QIAGEN Ingenuity Pathway Analysis (IPA) users have expressed interest in taking advantage of public single-cell expression data. Such data is readily available and easily accessible in IPA. We are hosting a 1hr training focused on some common use cases related to this topic.
You'll learn to:

Easily locate single-cell studies, samples or cell types of interest
Study pathways and networks pertaining to such projects to explore biological and cellular mechanisms
Investigate sample- and cell-level gene expression for biomarker investigation

Achieving Good Manufacturing Production (GxP) compliance with NGS (EMEA)
2024-09-04 10:00 - 10:30 (Europe/Helsinki) | Virtual - EMEA - CET
New guidelines for the viral safety evaluation of biotechnology products from the International Council for Harmonisation (ICH) recommend replacing multiple in vivo and in vitro assays with next-generation sequencing (NGS) to maintain good manufacturing practices.
If that sounds like a lot, we’ve got you covered. In this webinar, we’ll explore how you can easily apply NGS analysis to GxP with the QIAGEN CLC Genomics platform. Make compliance intrinsic to your workflow and ensure product quality, data integrity and patient safety.
You’ll learn how to:

Assess biosafety, ensure integrity and perform quality control in the biotech industry with NGS
Implement and maintain GxP with the QIAGEN CLC Genomics platform
Add your existing applications and extend their use through the CLC interface

Achieving Good Manufacturing Production (GxP) compliance with NGS (Americas)
2024-09-04 13:00 - 13:30 (America/Halifax) | Virtual - Americas - EST, United States

QIAGEN IPA new user training
2024-09-04 13:00 - 15:00, 2024-10-03 13:00 - 15:00 (America/Halifax) | Virtual - Americas - EST, United States
Are you new to QIAGEN Ingenuity Pathway Analysis (IPA) or interested in expanding your skill set? Join us as we learn more on large dataset analysis and knowledge base queries using QIAGEN IPA.
You’ll learn to:

Upload multiple dataset types (e.g., RNA-seq, proteomics, metabolomics) and perform interactive core/pathway analysis in IPA
Learn how to interpret different results, including pathways, key regulators, impact on biological functions/diseases and more
Compare different experimental conditions (e.g., single-cell clusters, disease types) and identify similarities and contrasts
Generate a network for hypothesis generation, even without a dataset or experimental design

Already have an IPA license? Install IPA and start using it now.
Learn more about IPA or request a free trial.

Custom patient cohorts: Making discoveries with curated genomics data
2024-09-05 13:00 - 14:00 (America/Halifax) | Virtual - Americas - EST, United States
Are you interested in exploring how you can evaluate phenotypic differences between custom cohorts? You can learn more about drug response, survival, co-expressing biomarkers, mutations and more based on gene expression.
In this webinar, you'll learn how to investigate patient cohorts using high-quality curated genomic repositories like the QIAGEN OmicSoft Lands database. You'll be able to to perform in-depth investigations across diverse data-sources, including GEO datasets, TCGA and more.
In this webinar, attendees will learn how to

Easily locate studies of interest using OmicSoft Lands APIs
Generate custom cohorts based on expression levels of biomarker(s) of interest
Thoroughly investigate drug response and patient survival for these custom cohorts
Study variants/mutations present in these patient population and their association with disease pathology

QIAGEN presents poster at 2024 European Congress of Pathology
2024-09-07 08:00 - 2024-09-11 17:00 (Europe/Helsinki) | Florence, Italy
QIAGEN will be at the 36th European Congress of Pathology (ECP) in Florence from September 7-11, 2024, in Florence, Italy.
At the event, be sure to check out our poster that we are presenting in collaboration with a leading pharmaceutical company showing how our clinical decision support software, QCI Interpret, provides rapid and accurate interpretation of gBRCA genes in a clinical lab setting. In the study, 10 partner labs were asked to assess 48 retrospective analyses of BRCA variants and compare their variant classifications with the automated classifications computed by QCI Interpret. Results showed QCI Interpret was concordant with 93% of all cases.

Featured Poster: Spadolini Pavilion (Upper Floor)
Molecular Pathology Session | September, 10, 2024, 9:30–10:30 a.m.
Poster number: 009. Title: “QIAGEN clinical decision support software provides rapid and accurate interpretation of gBRCA variants in a clinical lab setting”

Metatranscriptome analysis, annotation and pathways investigations using CLC Genomics Workbench
2024-09-10 13:00 - 14:30 (America/Halifax) | Virtual - Americas - EST, United States
Using CLC Genomics Workbench, we will go through a pipeline for analyzing metatranscriptome NGS data from microbial communities and perform pathways interpretation on it.

Import "raw" NGS sequencing data and prepare the samples for analysis
Find relevant annotated genomes with a curated reference database while removing ribosomal RNA with the SILVA database (database of rRNAs)
De novo assemble the unclassified reads into contigs to also find transcripts of taxa not present in the reference database
Map the reads to the assembled contigs and database · Build a functional profile of the samples to get an abundance of GO-terms.
Statistical analysis of the groups
Pathway analysis on the differential abundance analysis using MetaCyc database.

Expanding neoantigen discovery with COSMIC
2024-09-12 11:00 - 12:00 UTC | Virtual - Americas - EST, United States
Neoantigens are among the newest promising targets for cancer treatment. Unlike tumor-associated antigens, neoantigens are produced only by tumor cells. These unique molecular markers are highly visible to the immune system, making them ideal for personalized immunotherapies. They may also be able to predict both tumor survival prognosis and immune checkpoint blockade responses. Neoantigens are presented by human leukocyte antigen class I molecules (HLA-I) to T cells, providing an ideal pathway for detection by shotgun proteomics. To identify these elusive targets, scientists often rely on whole exome sequencing (WES)-derived data. However, this approach can miss rare or low-frequency mutations, especially in cancers with a low tumor mutational burden (TMB).
The Catalogue of Somatic Mutations in Cancer (COSMIC) can bridge this gap by providing researchers with detailed information about somatic mutations in human cancer. Unlock the full potential of neoantigen-targeted therapies and enhance traditional approaches like WES with our comprehensive, expert-curated knowledge base.
In this webinar, we’ll learn to:

Uncover and validate potential neoantigens with a recent peer-reviewed study that uses COSMIC mutation data from human hepatocellular carcinoma (HCC), a low-TMB cancer
Apply the benchmarking results of neoantigen detection performance using HCC-specific variants from COSMIC or DepMap
Take full advantage of the breadth and accuracy of COSMIC data with downloaded content and other resources

COSMIC’s scientific and curation team will also answer your questions live during the webinar.

Speaker: Kyle Nilson, PhD
Kyle Nilson, PhD, is a sequencing-focused molecular biologist with a background in biochemistry and technical support. As a field software trainer at QIAGEN Digital Insights, Dr. Nilson works closely with QIAGEN’s global bioinformatics team to provide direct customer support and assist with software training, implementation, and optimization. He earned his Ph.D. in molecular and cellular biology from the University of Iowa, where he studied the regulation of RNA polymerase II transcription and co-transcriptional mRNA processing. Dr. Nilson then completed his postdoctoral training at Penn State and Cornell University, focusing exclusively on next-generation sequencing method development to study chromatin.

OmicSoft Diseaseland Training
2024-09-17 13:00 - 14:30 (America/Halifax) | Virtual - Americas - EST, United States
Per feedback of scientists interested in taking advantage of non-oncological diseases (inflammatory, infectious, metabolic and more) as well as normal tissues (example toxicology/target safety assessment) omics, we are hosting this training focused OmicSoft Diseaseland. OmicSoft Diseaseland is a repository which contain high quality curated ‘omic data (RNA-seq, scRNA-seq, microarray and more) from diverse data-sources (example GEO, SRA, GTEx and many more). While this training will be focused on leveraging public data, users can use this knowledge to navigate through their institution’s internal lands (omic data repositories) as well.
Attendees will learn to perform queries similar to below

How is a gene (or a set of genes) expressed across different conditions? (Conditions = diseases, tissues, treatments, cell types and more)
How is expression of a gene correlated with expression of other genes?
For a list of genes can we generate a heatmap studying their expression across different conditions?
How do you get a list of biomarkers specific to a condition from public studies?

Third Annual Clinical Hereditary Disease Diagnostics Summit "Exome experts: Improving the interpretation and integration of exome testing in routine clinical care"
2024-09-26 11:00 - 12:30 UTC | Virtual - Americas - EST, United States
Industry leaders discuss how to improve the speed, precision and cost-effectiveness of clinical exome testing for newborn screening and rare and undiagnosed diseases
Clinical exome testing is revolutionizing the diagnosis of rare and inherited diseases. Its ability to quickly pinpoint the genetic causes of complex conditions has made it a critical component of personalized medicine, leading to earlier diagnoses, targeted treatments and improved patient outcomes. However, without the right strategies, databases and informatics tools, clinical exome testing remains inaccessible for many small to mid-sized laboratories.
The Third Annual Clinical Hereditary Disease Diagnostics Summit hosted by QIAGEN Digital Insights will examine the incredible opportunities—and challenges—of brining clinical exome testing in-house. Join industry leaders as they discuss how labs, regardless of size, budget and experience, can integrate exome testing into routine clinical care with transformative impact for providers and their patients.
Featured topics will include:

Emerging trends and recent technological advancements in genetic testing
Overcoming challenges of interpreting complex genetic data from genome, exome, and next-generation sequencing panels
How to integrate genetic testing into clinical practice with consideration of efficiency, cost, and ethics
Future directions for the field and how to prepare your lab for innovation

Investigating biomarkers with bulk and single-cell RNA-seq expression data
2024-09-26 13:00 - 14:30 (America/Halifax) | Virtual - Americas - EST, United States
QIAGEN Ingenuity Pathway Analysis (IPA) is designed to help you analyze and compare different types of 'omics data. In this webinar, we’ll compare bulk RNA-seq and single-cell RNA-seq data to identify common regulators/targets and see how those regulators/targets associate with your phenotype of interest. We will also use sample-level public data to validate gene expression of common genes in tissues and/or cell type of interest.
You'll learn how to:

Generate a Comparison Analysis for bulk and single-cell RNA-seq
Identify significant common genes with the Compare feature
Build a custom network associating common genes to a phenotype
Examine sample- and cell-level expression in OmicSoft content

RNA-seq data analysis and interpretation with Sankey plot update
2024-10-07 14:00 - 15:30 UTC | Virtual - Americas - EST, United States
For RNA-seq data, you will learn how to:

Import FASTQ files, cell matrix files and metadata and how to download references
Map reads to a reference genome and generate gene and transcript counts and QC reports displaying % mapped reads, knee plots, etc.
Generate visualizations of results, such as heatmaps, differential expression tables, PCA/PCOA plots, Venn diagrams, sankey plot and others
Easily customize RNA-seq workflows
Export publication-quality graphics, tables and reports
Send differential expression tables to QIAGEN Ingenuity Pathway Analysis directly from QIAGEN CLC Genomics Workbench to analyze and interpret relevant pathways

How to triage drug targets with curated, causal relationships data
2024-10-08 13:00 - 14:00 (America/Halifax) | Virtual - Americas - EST, United States
In the rapidly evolving landscape of drug discovery, the ability to integrate high-quality research findings into knowledge graphs is paramount. For over twenty years, our scientists have curated the relationships between genes, drugs, diseases, and pathways to power Ingenuity Pathway Analysis. Now, these data are available via our QIAGEN Biomedical KB-HD, which provides direct access to flat files, SQL APIs in Python and R, and the ability to export knowledge graph objects for analysis in Neo4j. In this talk, we will explore how to use this rich data resource to:

aggregate relevant findings across our comprehensive disease and gene ontologies
cross-reference clinical trial results to focus your research on genes upstream or downstream of known drug targets
filter causal relationships by the directionality of observed effects
combine the above methods to accelerate the drug discovery process

By demonstrating the underlying database live, we will show how the high-quality curated biomedical knowledge bases can be rapidly deployed, as well as how the underlying schema and ontologies could serve as a scaffold for integrating your own research. Overall, this demonstration will show the critical role of knowledge graphs in finding viable drug targets while avoiding potential adverse outcomes and toxicity.

Webinar: Streamline your hereditary diseases interpretation workflow with QCI Interpret
2024-10-10 11:00 - 12:00 UTC | Virtual Global Event (Times shown in EST)
Learn how QCI Interpret, clinical decision support software for variant interpretation and reporting, can help your lab rapidly identify pathogenic variants, improve diagnostic yields, and significantly reduce test turnaround time for hereditary diseases. Attendees will receive a demonstration of QCI Interpret’s unique capabilities and advanced features for germline variant interpretation with example workflows for carrier screening and whole-exome sequencing panels. Key highlights will include how your lab can expedite variant interpretation by leveraging the most extensive, manually curated knowledge base, dynamically compute pathogenicity based on ACMG guidelines for every variant with full transparency, and leverage QCI Interpret’s proprietary augmented molecular intelligence approach to literature curation and variant classification to streamline your interpretation workflow.
In this webinar, attendees will:

Receive a demonstration of QCI Interpret’s analysis and interpretation workflows for hereditary diseases using targeted and extended gene panels, including whole-genome and whole-exome sequencing.
Learn about QIAGEN’s proprietary expert curation process for the knowledge base in QCI Interpret.
Explore unique time-saving features within QCI Interpret, including phenotype-driven ranking and automation of ACMG guidelines.
Understand how QCI Interpret supports copy number variant (CNV) interpretation and reporting with bibliographic coverage of over 60,000 CNV case reports.

Speaker:

Elias Hage, PhD
Associate Director, Global Product Management
QIAGEN Digital Insights

Elias Hage, PhD, is the Associate Director of Global Product Management for Hereditary Disease and Oncology Applications at QIAGEN Digital Insights (QDI). In this role, he oversees the development, management, and optimization of QDI software, databases and services for genomic analysis and interpretation of hereditary disease and oncology cases. Prior to joining QDI, Dr. Hage served as a Global Product Manager at Agilent Technologies, where he managed the Genomics division flagship SaaS application (Alissa Interpret) and supported its usage globally in both research and IVD settings. Dr. Hage obtained his Ph.D. in virology and genomics from Hannover Medical School in Belgium.

QIAGEN at VEPTC 2024
2024-10-14 - 2024-10-16 | Palermo, Italy
Meet QIAGEN at the Variant Effect Prediction Training Course (VEPTC)
This year at the 2024 Variant Effect Prediction Training Course (VEPTC), QIAGEN will be showcasing our industry-leading next-generation sequencing (NGS) variant analysis, interpretation and reporting solutions. Trusted to analyze and interpret more than 4 million NGS patient test cases, QIAGEN Clinical Insight (QCI) is the industry’s leading clinical decision support platform by volume. Find out why nobody does variant analysis and interpretation better than QIAGEN at VEPTC 2024.
Learn more and schedule a VIP meeting with our experts at VEPTC 2024 here.

Gene therapy applications through knowledge graph explorations
2024-10-16 13:00 - 15:00 (America/Halifax) | Virtual - Americas - EST, United States
In gene therapy space, there is great interest in discovering new gene editing targets as well as identifying new indications for known targets though exploration of vector biology and studying biological mechanism underlying disease pathology. In this webinar, we will focus on how recently introduced Biomedical KB-AI can enable and accelerate such investigation. QIAGEN Biomedical KB-AI uses generative AI to identify novel relationships and patterns that may be missed by traditional methods and can provide a more comprehensive view of the biological landscape. Participants will learn about:

Biomedical KB-AI and its structure
How to easily search and filter results for vector system of interest through subgraph
How to thoroughly interrogate the subgraph to look for similarity between diseases and targets that can be targeted by vectors of interest
How to effectively use knowledge graph for drug repurposing applications

Master HGMD Professional: Virtual Training Session
2024-10-16 14:00 - 15:00 UTC
Back by popular demand, our live, interactive HGMD Professional sessions are designed to help you master the skills needed to navigate and use the industry-leading database like an expert. Offered on two dates—October 16, 2024, and October 23, 2024—these virtual training sessions will show you how to effectively leverage the extensive features and functionalities of HGMD Professional compared to its public counterpart.
Attendees will learn how to:

Distinguish clinically relevant variants from variants of unknown significance (VUS)

Curate genes using HGMD Professional’s accurate, up-to-date evidence

Identify the predominant genetic variant in a specific gene to understand the genetic mechanisms underlying associated diseases

Use batch search vs advanced search when you need to query a large number of mutations or variants at once.

Can't make Session 1? Register for Session 2 on October 23 here.

Introducing the RNA-seq Analysis Portal in QIAGEN IPA
2024-10-17 13:00 - 14:30 (America/Halifax) | Virtual - Americas - EST, United States
Get to know the RNA-seq Analysis Portal, a cloud-based platform you can access from within QIAGEN Ingenuity Pathway Analysis (IPA) that helps you analyze your RNA-seq expression data. Its predefined analysis pipelines let you calculate expression levels and identify differential expression and significant pathways, regulators, diseases and functions in just a few steps. The graphical views and interactive plots enable seamless exploration and refinement of your RNA-seq analysis results.
In this training you will learn how to:

Upload your own expression data (example raw FASTQ files) or start with a public dataset
Perform RNA-seq analysis and generate outputs such as heatmap, differential expression table, volcano plot and more
Export graphical and tabular results

Learn more about the IPA RNA-seq Analysis Portal.

Master HGMD Professional: Virtual Training Session
2024-10-23 10:00 - 11:00 UTC
Back by popular demand, our live, interactive HGMD Professional sessions are designed to help you master the skills needed to navigate and use the industry-leading database like an expert. This virtual training session will show you how to effectively leverage the extensive features and functionalities of HGMD Professional compared to its public counterpart.
Attendees will learn how to:

Distinguish clinically relevant variants from variants of unknown significance (VUS)

Curate genes using HGMD Professional’s accurate, up-to-date evidence

Identify the predominant genetic variant in a specific gene to understand the genetic mechanisms underlying associated diseases
Use batch search vs advanced search when you need to query a large number of mutations or variants at once.

2024 update: Long reads analysis with QIAGEN CLC Genomics Workbench
2024-10-24 13:00 - 14:30 (America/Halifax) | Virtual - Americas - EST, United States
This webinar will introduce users to the long read support plugin for Oxford Nanopore and PacBio sequencing reads in QIAGEN CLC Genomics Workbench.
Participants will learn how to:

Download and install needed plugins
Import data required for the analysis
Perform long read de novo assembly
Map reads to a reference and visualize an assembly
Use BLAST to investigate the contigs
Use additional long read tools: polish with short reads, structural variant calling
Use genome finishing tools: analyze and assemble contigs
Use analytical tools: RNA-seq analysis for long reads, classify long read amplicons for metagenomics

QIAGEN at the Precision Medicine Forum Berlin
2024-10-29 - 2024-10-30 | Berlin, Germany
Meet QIAGEN at the Precision Medicine Forum Berlin
This year at the 2024 Precision Medicine Forum Berlin, QIAGEN will showcase our barrier-breaking Sample to Insight Oncology solution. Combining targeted DNA and multimodal pan-cancer panels, one of the fastest and cheapest secondary analysis solutions in the market, and industry-leading variant interpretation and reporting software trusted to analyze and interpret over 4 million NGS patient test cases worldwide, our Sample to Insight Oncology solution is revolutionizing precision oncology testing.
Learn more and register here.

QIAGEN at ASHG 2024
2024-11-05 - 2024-11-09
Meet QIAGEN at the 2024 American Society of Human Genetics (ASHG) Annual Meeting
This year at the 2024 American Society of Human Genetics (ASHG) Annual Meeting, QIAGEN will showcase our Sample to Insight solutions for human genetics and inherited disease applications. From digital PCR technologies and actionable exome panels to one of the fastest and cheapest secondary analysis solutions in the market and industry-leading variant interpretation and reporting software trusted to analyze and interpret over 4 million NGS patient test cases worldwide, our Sample to Insight solutions are revolutionizing genetic testing.
Learn more and schedule a VIP meeting with our experts at ASHG 2024 here.

QIAGEN IPA new user training
2024-11-06 13:00 - 15:00 UTC | Virtual - Americas - EST, United States
Are you new to QIAGEN Ingenuity Pathway Analysis (IPA) or interested in expanding your skill set? Join us as we learn more on large dataset analysis and knowledge base queries using QIAGEN IPA.
You’ll learn how to:

Upload multiple dataset types (e.g., RNA-seq, proteomics, metabolomics) and perform interactive core/pathway analysis in IPA
Interpret different results, including pathways, key regulators, impact on biological functions/diseases and more
Compare different experimental conditions (e.g., single-cell clusters, disease types) and identify similarities and contrasts
Generate a network for hypothesis generation, even without a dataset or experimental design

Already have an IPA license? Install IPA and start using it now.
Learn more about IPA or request a free trial.

Exclusive Interactive Workshop: Master Clinical Variant Interpretation with QCI Interpret for Oncology
2024-11-07 11:00 - 13:00 UTC
An exclusive hands-on workshop to try QCI Interpret for Oncology
For US-based labs interested in learning more about QCI Interpret for Oncology, QIAGEN’s clinical decision support software for variant interpretation and reporting, we are hosting an exclusive, interactive virtual workshop where you can access and demo the software for free. Each attendee will be given a temporary license and a VCF file to run a case on the industry-leading software. Through a guided session, you will be able to see first-hand how QCI Interpret works, with full exploration of the software’s capabilities and features.
In this workshop, you will see how QCI Interpret:
• Dynamically computes pathogenicity and actionability based on the ACMG and AMP/ASCO/CAP guidelines for every variant in all cancer types with full transparency.
• Provides access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries to build customizable, oncologist-ready reports.
• Effortlessly streamlines case reviews by automatically selecting reportable variants, along with tailored treatments and trials.
Only 40 spots available. Must apply by October 25, 2024.
This workshop is an exclusive event limited to a select number of participants. To register, you must provide a work email and be selected by QIAGEN to attend. The workshop will be hosted on a US server and no customer data will be involved.
Learn more and register here.

Support Session for IPA Certification
2024-11-07 13:00 - 14:30 (Asia/Dubai) | Virtual - Americas - EST, United States
Join us for a 90-minute LIVE group session designed to address different technical questions regarding IPA certification. QIAGEN IPA scientists will answer different IPA related technical questions and clarify various topics per requests of IPA certification participants. If possible, please register for this session and let us know your questions by November 4, 2024.
Please note:

We strongly encourage you to submit your questions ahead of time through this registration form.
While questions submitted through this registration ahead of time will be prioritized, we will try to answer as many questions as possible in these 90 min.
The purpose of this session is NOT for QIAGEN scientist to answer IPA certification exam questions but rather explain concepts surrounding these questions. Example, for exam question asking how many molecules are mapped vs unmapped in the exam dataset, the QIAGEN scientist will not give you the number but if asked, will go over relevant steps of the data upload process.
Only those who signed up for IPA certification are invited to this session.

Questions we have so far:

Explain course structure and exam related details.
Go over recent update (RNA-seq analysis portal, new pathways, GWAS etc.) and cover this in context of this course.

Discover biomarkers, validate targets and identify variants with QDI software
2024-11-12 13:00 - 14:30 (America/Halifax) | Virtual - Americas - EST, United States
Learn how to leverage solutions from QIAGEN Digital Insights to discover biomarkers, validate targets, and identify variants.
Attendees will learn to:

Locate public studies of interest using OmicSoft DiseaseLand
Investigate expression of genes of interest across different treatments, disease states, etc.
Identify variants of interest for candidate biomarkers and targets using Human Gene Mutation Database (HGMD)
Leverage the QIAGEN Knowledgebase in Ingenuity Pathway Analysis (IPA) to explore and extend findings from OmicSoft DiseaseLand and HGMD
Access data from OmicSoft, HGMD and IPA in ways that are helpful for data scientists

Webinar: Pharmacogenomics - One tool to decode drug response to variation in the genome
2024-11-13 10:00 - 11:00 (America/New_York)
Each year, more than 134 million patients experience adverse drug events, causing 2.4 million deaths worldwide. What if there was a better way to develop and prescribe safer, more effective drugs based on the unique genetic information of every individual?
In this webinar, learn about a game-changing solution for labs and pharmaceutical companies to rapidly and confidently translate complex pharmacogenomics (PGx) data into evidence-backed insights to inform therapeutic outcomes. QIAGEN Pharmacogenomic Insights (PGXI) is a new expert-curated knowledgebase solution that provides comprehensive access to verified and up-to-date data from multiple PGx sources, including the FDA, CPIC, DPWG, PharmVar, and PubMed. Built upon a legacy platform used to deliver more than 1.6 million PGx annotations for more than 250 clinical research laboratories, PGXI seamlessly integrates into existing or new workflows to automate the annotation of PGx data from all platforms, including NGS and arrays. Within minutes, users can retrieve a custom output of relevant information, including relevant conditions associated with queried genes of interest, relevant drug-gene associations, and curated literature evidence for alleles in question.
In this webinar, you will learn:

How PGXI can help your lab efficiently and consistently identify medications associated with adverse effects.
What expert-curated content sources are available in PGXI, eliminating the need to consult multiple databases and saving you significant time and money.
How to use PGXI to seamlessly scale your PGXI workflow and stay at the cutting edge of PGx research.

Plus, if eligible, webinar attendees can try PGXI for free with an exclusive trial offer from QIAGEN. There’s an easier and faster way to translate PGx data into insights. Don’t miss this opportunity to elevate and transform your PGx program.
Learn more and register here.
